We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

GR Defect in Sputum Cells in COPD

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00159276
First Posted: September 12, 2005
Last Update Posted: August 13, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
AstraZeneca
Information provided by:
Imperial College London
  Purpose
To investigate a possible mechanism of the GR defect in patients with severe COPD by studying the effect of dexamethasone (Dex) on GR-GRE binding, expression of inflammatory and anti-inflammatory factors such as IL-6, IL-8, MKP-1, GILZ, SLPI production in sputum cells

Condition Intervention
Chronic Obstructive Pulmonary Disease (COPD) Procedure: Induced Sputum

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: GR Defect in Sputum Cells in COPD

Further study details as provided by Imperial College London:

Estimated Enrollment: 30
Study Start Date: December 2005
Estimated Study Completion Date: December 2008
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   35 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • Patients with moderate (stage II, GOLD) COPD or subjects who are healthy smokers or subjects who are non-smokers.
  • Written informed consent

Exclusion Criteria:

  • Current upper respiratory tract infections
  • Any significant disease or disorder (e.g. cardiovascular, pulmonary (other than asthma), gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subjects ability to participate in the study
  • Subjects not considered capable, as judged by the investigator, of following instructions of the study, e.g. because of a history of alcohol or drug abuse or any other reason
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00159276


Locations
United Kingdom
Section of Airway Disease, Asthma Lab, Imperial College London, Royal Brompton Hospital
London, United Kingdom, SW3 6LY
Sponsors and Collaborators
Imperial College London
AstraZeneca
Investigators
Principal Investigator: Sergei A Kharitonov, MD PhD Imperial College London
  More Information

ClinicalTrials.gov Identifier: NCT00159276     History of Changes
Other Study ID Numbers: D5899N00007A
First Submitted: September 8, 2005
First Posted: September 12, 2005
Last Update Posted: August 13, 2008
Last Verified: August 2008

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases